DHA revisions offer hope to health claim rejections

By Stephen Daniells

- Last updated on GMT

The affirmation that the omega-3 DHA can benefit cognitive and eye health offers hope to previously rejected claims. And it's business as usual regarding the overall health claims process, despite ratification of the Lisbon Treaty, said a European Commission representative.

At the NutraIngredients Health Claims 2010 conference in Brussels, the EC's Lars Korsholm explained the regulatory state-of-play for DHA claims.

“I think it will offer some hope to previously rejected claims in the sense that these claims that are now subject for discussion are generic in the sense that if other food business operators than those who actually submitted the application can claim to fulfill the conditions of use then they are equally entitled to use the claim,” ​explains Korsholm.

The statements come in relation to an October decision whereby the European Food Safety Authority (EFSA) affirmed that the omega-3 fatty acids, DHA and ALA, can benefit eye and cognitive development in babies.

Responding to the public comment period for Merck Selbstmedikation GmbH’s article 14 cognitive development claim that was rejected in March, EFSA affirmed its original stance that there was no need for additional supplementation of DHA (docosahexaenoic acid) and ALA (alpha-linolenic acid) because it already existed at adequate levels in the diet.

It supported their role in foetal and newborn eye and brain development but said there was an adequate supply in breast milk.

“DHA has a structural and functional role in the brain and retina and maternal DHA intake can contribute to the early development of the eye and normal cognitive development in the foetus and the brain-fed infant,”​ wrote Dr Juliane Kleiner, head of EFSA's Panel on Dietetic Products, Nutrition and Allergies (NDA).

But in regard to the need for supplementation she added: “…while DHA can be synthesised in the human body from its precursor essential fatty acid ALA to a certain extent, the human foetus appears to be largely dependent on placental transfer of DHA from the mother derived either from her diet, from synthesis or from stores in adipose tissue. The Panel also noted that most DHA is provided to the breast-fed infant via breast milk in which the DHA concentration is dependent both on maternal dietary intake and maternal DHA stores, while the contribution by synthesis is low.”

“All these factors, and the fact DHA supplementation was administered in most studies in addition to background diets already providing ALA and DHA in unspecified amounts, may have accounted for the insufficient evidence for a causal relationship between maternal supplementation with DHA and visual and cognitive benefits in their offspring.”

Related news

Show more

Related products

show more

Algal Oil or Fish Oil: Which Should I Choose?

Algal Oil or Fish Oil: Which Should I Choose?

Content provided by GC Rieber VivoMega™ | 04-Nov-2024 | Infographic

Are you fishing for answers when it comes to omega-3s from fish oil vs. algal oil? Do you find yourself asking if EPA or DHA from fish oil is the same...

Research for Restorative Sleep: Levagen®+

Research for Restorative Sleep: Levagen®+

Content provided by Gencor | 27-Sep-2024 | White Paper

Levagen®+ is Gencor's branded Palmitoylethanolamide (PEA), an endogenous fatty acid amide naturally found in every cell of the body.

Comprehensive Nutritional Lipid Solutions

Comprehensive Nutritional Lipid Solutions

Content provided by INNOBIO Corporation Limited | 24-Sep-2024 | White Paper

INNOBIO specializes in high-quality DurOmega® functional lipid products, emphasizing enhanced fatty acid quality and application performance.

Research for Restorative Sleep: Levagen®+

Research for Restorative Sleep: Levagen®+

Content provided by Gencor | 09-Sep-2024 | White Paper

Levagen®+ is Gencor's branded Palmitoylethanolamide (PEA), an endogenous fatty acid amide naturally found in every cell of the body.

Related suppliers

Follow us

Products

View more

Webinars